Klaus Bleymaier

Title: Innovations by Klaus Bleymaier in Pharmaceutical Compositions

Introduction

Klaus Bleymaier is a prominent inventor based in Vienna, Austria, known for his contributions to the field of pharmaceuticals. With a total of two patents to his name, Bleymaier focuses on developing abuse-deterrent pharmaceutical compositions aimed at mitigating the potential for drug abuse.

Latest Patents

Bleymaier’s latest innovations include two key patents related to abuse-deterrent formulations. The first patent discloses an abuse-deterrent pharmaceutical composition comprising a drug with an enzyme-reactive functional group. This composition includes a drug that has an abuse potential and a drug-processing enzyme, which ensures the drug remains in a storage stable, enzyme-reactive state until it is required for use. The second patent presents pharmaceutical compositions that specifically involve oxycodone in combination with an oxycodone-processing enzyme, designed to maintain the drug in a stable state and prevent enzymatic activity that could lead to its abuse.

Career Highlights

Klaus Bleymaier works at G.L. Pharma GmbH, where he continues to contribute to innovative pharmaceutical solutions. His deep understanding of pharmaceutical chemistry and drug interactions has positioned him as an essential figure in his company and the broader industry.

Collaborations

Throughout his career, Bleymaier has collaborated with notable colleagues such as Georg Guebitz and Katrin Greimel. These collaborations have been instrumental in advancing research and development efforts at G.L. Pharma, paving the way for new approaches to drug formulation.

Conclusion

Klaus Bleymaier’s work in developing abuse-deterrent pharmaceutical compositions demonstrates his commitment to addressing significant challenges in the pharmaceutical industry. With his innovative patents and collaborative spirit, Bleymaier continues to play a vital role in enhancing drug safety and efficacy. His contributions may lead to a meaningful impact in the ongoing battle against prescription drug abuse.